Announcement

Collapse
No announcement yet.

Fortuna Fix Company selects Scientific Advisory Board to move therapy forward

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Fortuna Fix Company selects Scientific Advisory Board to move therapy forward

    Fortuna is a private, clinical-stage biotech company with a patented direct cell reprogramming technology platform together with a patented bio-scaffolding technology for treatment of neurodegenerative diseases and neurotrauma. The company is focused on clinical development of its platforms for a range of neurodegenerative diseases including SCI, Parkinsons disease, stroke, TBI, and ALS. The company has developed a proprietary fully automated GMP manufacturing system for production of drNPC, initially to be used in clinical trials in Parkinsons disease and Spinal Cord Injury.

    Press Release and additional information LINK.
    http://spinalcordresearchandadvocacy.wordpress.com/

  • #2
    I should have added that Fortuna’s two flagship technologies — autologous directly reprogrammed neural precursor cells (“drNPC”) and Regeneration Matrix (“RMx™”) — are poised to lead a revolution in neuro-regeneration. This is the work of Jan-Eric Ahlfors. He did 2 presentations at Working 2 Walk 2015. His work was being done at New World Laboratories in Canada.

    http://spinalcordresearchandadvocacy.wordpress.com/

    Comment


    • #3
      This sounds good, but I feel like I've read this article many times over the past 50 years. I'll reserve my excitement until they have a place to sign up for treatment in the U.S.

      Comment


      • #4
        Originally posted by khmorgan View Post
        This sounds good, but I feel like I've read this article many times over the past 50 years. I'll reserve my excitement until they have a place to sign up for treatment in the U.S.
        You're right. I have no idea why I bothered posting the information here. My bad...
        http://spinalcordresearchandadvocacy.wordpress.com/

        Comment


        • #5
          Keep it coming, any news on commercial organisations is very interesting.

          News on research is interesting, but when a commercial organisation does something it feels closer to actually happening.

          Comment


          • #6
            They presented stuff on W2W about clinical result. Do we know anymore on that?
            Last edited by void; 05-07-2017, 01:16 PM.
            Debating on CareCure is like participating in the special-olympics. You may win, but you're still disabled.

            Comment


            • #7
              Originally posted by void View Post
              They presented stuff on W2W about clinical result. Do we know anymore on that?
              With the formation of the quality SAB, it's my understanding we'll be hearing more soon. I'll post it at the blog for anyone interested.
              http://spinalcordresearchandadvocacy.wordpress.com/

              Comment


              • #8
                Amgen bets on stem cell company Fortuna Fix in $25M round
                https://endpts.com/amgen-bets-on-ste...-in-25m-round/
                KB

                Comment


                • #9
                  Today's announcement on funding:

                  https://spinalcordresearchandadvocac...-shareholders/
                  http://spinalcordresearchandadvocacy.wordpress.com/

                  Comment


                  • #10
                    question: there used to be a listing on clinicaltrials.gov for what I thought was this trial in russia and it was currently underway I think in phase one or two... Is this about that same trial, but they are going to repeat it in America... I couldn't find that listing now
                    "That's not smog! It's SMUG!! " - randy marsh, southpark

                    "what???? , you don't 'all' wear a poop sac?.... DAMNIT BONNIE, YOU LIED TO ME ABOUT THE POOP SAC!!!! "


                    2010 SCINet Clinical Trial Support Squad Member
                    Please join me and donate a dollar a day at http://justadollarplease.org and copy and paste this message to the bottom of your signature

                    Comment


                    • #11
                      I believe that was discontinued pilot study. The funding now is for a Ph 1 & 2 for PD and SCI.
                      http://spinalcordresearchandadvocacy.wordpress.com/

                      Comment


                      • #12
                        Originally posted by GRAMMY View Post
                        I believe that was discontinued pilot study. The funding now is for a Ph 1 & 2 for PD and SCI.
                        https://spinalcordresearchandadvocac...unite-to-cure/

                        With its fully automated manufacturing system, Fortuna aims to be the first to manufacture and bring to the clinic personalized neural precursor cells for treatment of diseases in the fields of neurodegeneration and neurotrauma. Manufacturing of autologous drNPCs is accomplished with a rapid, high throughput, and fully automated process, which does not involve engineering, animal components, or staged pluripotency. Patients suffering from neurotrauma or neurodegeneration will be able to get treatment with their own neural cells providing functional integration without immunosuppression or ethical issues (the technology uses no fetal, embryonic-like, or other ethically challenging processes).
                        there’s a really good video in the link of Ahlfors during the panel.

                        Not sure if Grammy was going to post this, so I just added it to this thread.

                        Comment


                        • #13
                          Thank you nphuskers. I didn't put the post at carecure since this isn't an "on the market" cure that is ready to purchase. I could have added this portion to the piece in my post on the SCI Research and Science Report if case anyone is interested in the company and progress.

                          Fortuna Fix Announces the Appointment of Madhavan Balachandran to the Board of Directors;

                          Focusing on its Manufacturing, Fortuna Fix (Fortuna), a private Regenerative Medicine company announced today the appointment of Mr Madhavan Balachandran to its board of directors, bringing Mr Balachandran's extensive experience in chemistry, manufacturing and controls (CMC) to Fortuna and reinforcing the company's commitment to excellence in cell manufacturing. Mr. Balachandran retired in 2017 after spending 20 years at Amgen where he was Executive Vice President of Operations. As EVP Operations, he was responsible for Amgen's manufacturing, quality, process development, supply chain, and engineering functions, managing a group of 5,800 employees.


                          Joining the Board of Fortuna is a tremendous opportunity for me to be part of a company with a leading-edge technology in the field of neural cell therapeutics with a groundbreaking vision of developing personalized products to transform the CNS field. Cell therapies have the potential to truly change healthcare and make a significant and positive impact on the lives of patients, said Mr. Balachandran.


                          Jan-Eric Ahlfors, CEO of Fortuna Fix Inc., welcomed Mr. Balachandran, saying, The appointment of Mr. Balachandran to the Fortuna board brings broad CMC expertise to the company. As a company, we have prioritized fully automated manufacturing for production of our personalized directly reprogrammed neural precursor cells (drNPCs) as we recognize manufacturing as a significant hurdle most companies face in large-scale manufacturing of cellular therapies. We look forward to Mr. Balachandran's expertise and guidance as we advance clinical development of our programs.
                          Last edited by GRAMMY; 06-16-2018, 04:05 PM.
                          http://spinalcordresearchandadvocacy.wordpress.com/

                          Comment

                          Working...
                          X